Finance

Dova Pharmaceuticals, Inc. Announces Pricing of Offering of Common Stock

February 23, 2018

DURHAM, N.C., Feb. 22, 2018 (GLOBE NEWSWIRE) — Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a public offering price of […]

Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy

February 23, 2018

SAN DIEGO, Feb. 23, 2018 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the California Institute for Regenerative Medicine (CIRM) awarded the Company a $4.0 million grant to advance FT516 into a first-in-human clinical trial. FT516 […]

Advaxis Announces Proposed Public Offering of Common Stock

February 22, 2018

PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company (“Advaxis” or the “Company”) focused on the discovery, development and commercialization of cancer immunotherapies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Advaxis intends to grant the underwriters a 30-day option to purchase up to […]

Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock

February 22, 2018

BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $32.00 per share, for gross proceeds of $176 million before deducting estimated underwriting discounts and commissions […]

Innovus Pharma Announces the Complete Repayment in Cash of its Financial Obligations from its Acquisition of its Beyond Human® Assets

February 22, 2018

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that it has completed the repayment in cash of the principal amount of […]

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

February 22, 2018

COPENHAGEN, Denmark, Feb. 21, 2018 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 3,947,368 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $57.00 per ADS. All of the ADSs […]

WuXi STA and Regulus Announce microRNA Development and Manufacturing Collaboration

February 22, 2018

Agreement follows the recent opening of WuXi STA’s oligonucleotide R&D labs in China and the USA SHANGHAI, 22 Feb 2018: STA Pharmaceutical Co., Ltd. (STA), a WuXi AppTec group company and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing, and Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery […]

Dova Pharmaceuticals, Inc. Announces Proposed Offering of Common Stock

February 21, 2018

DURHAM, N.C., Feb. 20, 2018 (GLOBE NEWSWIRE) — Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. All of the shares in […]

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

February 21, 2018

COPENHAGEN, Denmark, Feb. 20, 2018 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis. All of the ADSs are being offered by Ascendis. In addition, Ascendis […]

Aimmune Therapeutics Announces Proposed Public Offering of Common Stock

February 21, 2018

BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has commenced an underwritten public offering of up to $150,000,000 of shares of its common stock. All of the shares to be sold in the offering will be offered by Aimmune. In addition, Aimmune expects […]

ORIC Pharmaceuticals Announces $50 Million Series C Financing to Support Novel Therapies for Treatment-Resistant Cancers

February 21, 2018

SOUTH SAN FRANCISCO, Calif., Feb. 21, 2018 /PRNewswire/ — ORIC Pharmaceuticals, a clinical-stage oncology company focused on discovery and development of novel therapies against treatment-resistant cancers, announced the completion of a $50 million Series C preferred stock financing. This financing brings the total equity capital the Company has raised to over $119 million. New investors […]

Ashfield launches new commercial model to improve ROI

February 21, 2018

Ashfield, part of UDG Healthcare, a global leader in providing outsourced healthcare services, has announced the launch of a pioneering new commercial model called The Ashfield Solution. In response to global market trends, The Ashfield Solution is an agile, multi-channel engagement model underpinned by a field analytics engine. The proprietary solution addresses the challenges of […]

Dynavax Secures $175 Million in Non-Dilutive Debt Financing

February 20, 2018

BERKELEY, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) — Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that it has closed on a $175 million non-dilutive term loan agreement with CRG LP, a healthcare focused investment firm. Dynavax will receive $100 million in a first tranche and up to an additional $75 million may be borrowed in a […]

Moleculin Announces Pricing of $9 Million Registered Direct Offering

February 19, 2018

HOUSTON, TX–(Marketwired – February 16, 2018) – Moleculin Biotech, Inc., (NASDAQ: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced […]

Pieris Pharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters’ Option to Purchase Additional Shares

February 19, 2018

BOSTON, MA–(Marketwired – February 16, 2018) – Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the closing of its previously announced underwritten public offering and the exercise in full of the underwriters’ option to purchase additional shares. […]

Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

February 19, 2018

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2018 /PRNewswire/ — Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that on January 24, 2018 the Compensation Committee of Rigel’s Board of Directors approved the grant of inducement stock options to purchase an aggregate of 30,000 shares of common stock to one new employee. This award was granted pursuant to […]

Catalyst Biosciences Announces Closing of Public Offering of Common Stock

February 16, 2018

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced the closing of an underwritten public offering of 3,382,352 shares of its common stock, offered at a price of $34.00 per share to the […]

Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares

February 16, 2018

Heidelberg, Germany, February 15, 2018 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the closing of its previously announced public offering of 13,225,000 of its common shares at a public offering price of $2.00 per common share. The total includes 1,725,000 common […]

Amicus Therapeutics Prices Underwritten Offering of Common Stock

February 16, 2018

CRANBURY, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq:FOLD) today announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share. The gross proceeds from the offering to Amicus are expected to be $300 million, before deducting underwriting discounts and commissions and estimated offering expenses payable […]

Buffett’s Firm Invests in Drugmaker Teva, Trims Phillips 66

February 15, 2018

OMAHA, NEB. Billionaire Warren Buffett’s company on Wednesday revealed a new investment in struggling Israeli drugmaker Teva Pharmaceuticals and trimmed its holdings in oil refiner Phillips 66 by selling 35 million shares back to the company for $3.3 billion.   Berkshire Hathaway Inc. disclosed those moves and several other tweaks to its stock holdings in […]

Amicus Therapeutics Announces Public Offering of Common Stock

February 15, 2018

CRANBURY, N.J., Feb. 14, 2018 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq:FOLD) today announced it has commenced a $250 million underwritten public offering of its common stock. J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as joint lead book-running managers, Cowen and Leerink Partners LLC are acting as co-book-running managers, and BofA […]

ABAC Therapeutics Announces €16 Million Series A to Develop Therapeutic Solutions to Fight Antibiotic-Resistant Bacteria

February 15, 2018

MADRID and BARCELONA, Spain, February 15, 2018 /PRNewswire/ —   Proceeds to support development of multiple novel first-in-class antibiotics   ABAC Therapeutics (ABAC), a leader in pathogen-specific antibiotics, announced today the closing of a €16 million Series A round. The financing was led by Pontifax with participation from the Global Health Science Fund (jointly established […]

Debiopharm Continues the Fight Against Antibiotic Resistance With Investment in ABAC Therapeutics Inc.

February 15, 2018

LAUSANNE, Switzerland, February 15, 2018 /PRNewswire/ —   ABAC develops new targeted antibiotics for patients with severe infections   Debiopharm Group ™ announces an investment in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics Inc. This investment was made through the Debiopharm Innovation Fund, its strategic investment fund, and illustrates the […]

National Cancer Institute Awards Tosk $2 Million Cancer Drug Development Grant

February 15, 2018

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Tosk, Inc. announced today that it has received a two-year, $2 million Phase II SIBR grant from the National Cancer Institute (NCI) to support its kRAS oncogene drug research and development program, a high priority for the NCI.   Some 40 percent of all cancer patients carry an oncogenic kRAS gene that […]

Catalyst Biosciences Announces Pricing of Public Offering of Common Stock

February 14, 2018

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced the pricing of an underwritten public offering of 2,941,176 shares of its common stock, offered at a price of $34.00 per share to the […]

Synergy Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 14, 2018

NEW YORK–(BUSINESS WIRE)–Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that the Compensation Committee of the Board of Directors of Synergy approved the grant of inducement stock options to purchase 289,000 shares of Synergy common stock to 193 former contract sales representatives that […]

Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock

February 14, 2018

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ra Pharmaceuticals, Inc. (NASDAQ:RARX) (“Ra Pharma”) today announced that it intends to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering. Ra Pharma expects to grant the underwriters a 30-day option to purchase up to $7.5 million of additional shares of its […]

Ferring Announces 30 Million CHF Investment in New Biotech Centre in Switzerland

February 14, 2018

SAINT-PREX, Switzerland–(BUSINESS WIRE)–Ferring Pharmaceuticals announced today that it is expanding its capabilities in biologics through a new biotech centre which will be installed at the company’s existing headquarters and manufacturing site in Saint-Prex, Switzerland.   “Ferring is committed to investing in innovative technology platforms to create new solutions for patients in our core areas of […]

Celgene Announces Additional $5 Billion Share Repurchase Authorization

February 14, 2018

SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced the Company’s Board of Directors authorized the repurchase of an additional $5 billion of the Company’s common stock. This open-ended program is effective immediately. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Celgene’s management and […]

FEEDBACK